Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Share-based Compensation (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Share-based Compensation for 3 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 27.24% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Dec 2025, down 2.28% year-over-year, with the annual reading at $6.8 million for FY2025, 2.28% down from the prior year.
  • Share-based Compensation for Q4 2025 was $1.6 million at Artiva Biotherapeutics, down from $1.6 million in the prior quarter.
  • The five-year high for Share-based Compensation was $2.2 million in Q4 2024, with the low at $1.4 million in Q3 2023.
  • Average Share-based Compensation over 3 years is $1.7 million, with a median of $1.6 million recorded in 2025.
  • The sharpest move saw Share-based Compensation surged 56.9% in 2024, then decreased 27.24% in 2025.
  • Over 3 years, Share-based Compensation stood at $1.4 million in 2023, then skyrocketed by 56.9% to $2.2 million in 2024, then decreased by 27.24% to $1.6 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $1.6 million, $1.6 million, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.